Portfolio News
Sofinnova Crossover
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
• Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026
• Cash runway guidance remains unchanged from July 30, 20262
• Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026
• Key highlights from the first half of 2026 and recent Company updates
• Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results
Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.
To read the full press release please visit the Inventiva website.
Related News
AFYREN and MINASOLVE Announce Partnership Agreement to Jointly Develop Key Bio-Based Molecules for the Fragrances Industry at Industrial Scale
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands
BrightHeart Expands Its AI Platform in Europe to Bring Greater Confidence and Consistency to Prenatal Ultrasound